TECH BUYER Mar 2023 - IDC Perspective - Doc # US50415923
Is the Metaverse Virtually a Reality for Life Science R&D?
This IDC Perspective reviews the significant potential of the metaverse and how it could transform the life science industry. It covers key use cases, analyzes the vendor landscape, reviews implementation challenges, and provides guidance to the technology buyer.
"As clinical trials go remote and the ask for the personal touch heightens, the metaverse will deepen patient engagement, shape patient behaviors, and transform patient and provider training. There will be increasing adoption of virtual reality in digital therapeutics to treat mental health disorders. Immersiveness will serve as a key differentiator, multiple use cases and multiple technologies will converge over time and will reshape existing models and patient experiences. On the long run, the metaverse will transform the way decentralized clinical trials are implemented. The reality is that the application of the metaverse in pharma is no more virtual," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.
IDC Health Insights: Worldwide Life Science R&D Strategy and Technology
Dassault Systemes SE, Wipro Limited, NVIDIA Corporation, Luminopia Inc., Tata Consultancy Services Limited, Atos SE, BehaVR Inc., Pear Therapeutics Inc., Schrodinger, LLC, Nanome Inc., Siemens AG, Nunaps, NTT DATA Corporation, AppliedVR, Inc., Infosys Limited
Augmented and virtual reality, Internet of things, Technology buyer, Wearables
List of Figures
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.